Abstract Purpose: Neoadjuvant therapy in thyroid cancer has emerged as a promising strategy for selected patients with locally advanced disease, but its rationale and clinical impact vary substantially across histologies. Methods: This comment examines the current evidence and clinical rationale for neoadjuvant therapy across anaplastic, differentiated and medullary thyroid carcinomas. Results: For BRAF V600E-mutated anaplastic thyroid carcinoma, targeted […]
Anaplastic thyroid cancer (ATC) is a highly aggressive histologic subtype of thyroid malignancy. Its rarity, rapidly progressive clinical course, along with limitations in health-care resources make management particularly challenging in Latin America. In recent years, substantial advances in the understanding of ATC biology have led to modifications in therapeutic strategies. This consensus aims to raise […]
Abstract Background: Brain metastases (BMs) from nonanaplastic follicular cell–derived thyroid carcinoma (hereinafter referred to as non-ATC) are rare and not well characterized, with limited evidence guiding treatment and prognostic stratification. We aimed to describe clinical features, treatment patterns, and outcomes of patients with BMs from non-ATC and to develop and validate a disease-specific prognostic score. […]
Abstract Purpose: Anaplastic thyroid carcinoma (ATC) is an aggressive malignancy with high mortality. Approximately 50% harbor the BRAF V600E mutation, for which dabrafenib-trametinib (DT) has been associated with improved survival (OS). Prompt diagnosis and access to molecular testing and targeted therapy are critical for outcomes. We evaluated diagnostic and therapeutic barriers in ATC patients treated in Buenos […]
Letter to the editor: When Guidelines Meet Reality: Implementing the 2025 ATA Recommendations for Differentiated Thyroid Cancer in Limited-Resource Settings
